Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc. (CLDI) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cldi · stock forecast · 2 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 2 Wall Street analysts in the past 3 months
Buy
2 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$9.00
Consensus
$5.50
+3042.9% upside
Low
$2.00
Median: $5.5 · Last Close: $0.17
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.17 | ↓ 3.22% |
1-day model range: $0.16–$0.17. Peak: $0.17 (-3.22%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · CLDI · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-05-15 | Baird | Maintains | Outperform→Outperform |
| 2024-03-21 | Baird | Maintains | Outperform→Outperform |
| 2024-03-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Calidi Biotherapeutics, Inc. (CLDI) stock. Of the recent 3 rating actions, 0 were upgrades and 0 were downgrades. 2 analysts currently cover CLDI.
Analyst Recommendation Trends
CLDI analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
Revenue Next Year
$0M
EPS This Year
$-44.34
EPS Next Year
$-7.44
↓ 83.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast CLDI EPS of $-44.34 for the current fiscal year, based on estimates from 1 analysts. The CLDI revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CLDI stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CLDI price target is $5.50 (+3042.9% upside), with an analyst consensus of Buy.
The CLDI short-term stock prediction for tomorrow is $0.17 (-3.22%).
Calidi Biotherapeutics, Inc. trades on AMEX under the ticker CLDI. The CLDI stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
CLDI forecast · 8 questionsAccording to 2 Wall Street analysts, the average 12-month CLDI price target is $5.50, with a high forecast of $9.00 and a low of $2.00. The median price target is shown in the chart above when available. This implies +3042.9% potential upside from the current price of $0.17.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.